Check out the results of the RASTEN study, a phase III randomized trial in a homogenous population of lung cancer patients, which investigates the role of low molecular weight heparin (LMWH) in the prevention of thrombosis.
The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).
Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.
Check out the results of the RASTEN study, a phase III randomized trial in a homogenous population of lung cancer patients, which investigates the role of low molecular weight heparin (LMWH) in the prevention of thrombosis.